New Sandoz chief Richard Saynor says the division is undergoing a transformation towards building a generics-focused business. Meanwhile, the company is still waiting to close the sale of its US oral-dose and dermatology operations to Aurobindo.
Sandoz’ new chief executive officer Richard Saynor is embarking on making the Novartis subsidiary more of a “generics-focused business,” even as the company expects to exit the world’s largest market for oral-dose and skincare generics within the next few weeks.
Insisting that Sandoz was “on track” with a transformation project to which his predecessor, Richard Francis, had felt unable to...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
